Welcome to Helix Talk, a podcast presented by the Rosalm Franklin University College of Pharmacy.

This podcast is produced by pharmacy faculty to supplement study material and provide relevant drug and professional topics.

We're hoping that our real-life clinical pearls and discussions will help you stay up to date

and improve your pharmacy knowledge.

This is an educational production, copyright Rosalind Franklin University of Medicine and Science.

This podcast contains general information for educational purposes only. This is not professional advice and should

not be used in lieu of obtaining advice from a qualified healthcare provider. And now, on to the show.

Welcome to Helix Talk. I'm Dr. Kane. I'm Dr. Schumann. And I'm Dr. Patel.

For those of you who don't know, Helix Talk is the new rebranded podcast for Rosalind Franklin University's College of Pharmacy.

The new content will not only include the top 200 drugs, but it will include current topics in pharmacy, drug class reviews, professional topics, etc.

And if you want to hear anything about a specific topic, just email us.

We'd love to hear some of your feedback on things that may be interesting to you.

And no worries, if you really wanted to go back to some of our older Top 200 Drugs

Podcasts, they're all still under the same URL.

And you can access them at helixtalk.com. So without further ado,

today we're talking about the new lipid guidelines that were released by the ACC and AHA in 2013,

and we're going to talk about how they impact clinical practice. So we were long due for these

guidelines. We had ATP three guidelines published in 2001, and

also the same organization then came up with an update in 2004. So between 2004 and 2013,

there are a lot of good studies that came about that needed to be summarized and put into

practice. So this is what the ACCAHA 2013 guidelines are doing.

So as far as what's new, the main thing with that is that these LDL goals, boom,

...